Peptic Ulcer Market Report 2026

The peptic ulcer market size has grown steadily in recent years. It will grow from $4.22 billion in 2025 to $4.35 billion in 2026 at a compound annual growth rate (CAGR) of 3.3%. The growth in the historic period can be attributed to high prevalence of h. pylori infections, limited awareness of peptic ulcer complications, widespread use of nsaids, traditional symptomatic treatments, inadequate early diagnosis.

The peptic ulcer market size is expected to see steady growth in the next few years. It will grow to $5.16 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to increasing adoption of proton pump inhibitors and antibiotics, growth in hospital and private clinic treatment facilities, rising awareness about preventive care, innovation in non-invasive diagnostic techniques, expansion of e-commerce and retail pharmacy distribution channels. Major trends in the forecast period include rising adoption of ai-based diagnostic tools, personalized ulcer treatments using genomics, use of cloud and big data for patient monitoring, integration of iot devices for remote symptom tracking, advanced manufacturing of ulcer therapeutics.

The increasing prevalence of obesity is expected to drive the growth of the peptic ulcer market in the coming years. Obesity is a medical condition marked by excessive body fat accumulation, generally defined by a body mass index of 30 or higher. It develops due to a combination of genetic, environmental, and lifestyle factors, including unhealthy dietary habits and insufficient physical activity. Obesity contributes to peptic ulcer formation by increasing gastric acid production, weakening the stomach’s protective mucosal barrier, and promoting inflammation within the gastrointestinal tract. This inflammatory response can further elevate the risk of ulcer development. For instance, in May 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, around 35 million children under the age of five were reported to be overweight in 2024. Therefore, the rising prevalence of obesity is contributing to the growth of the peptic ulcer market.

The rise in smoking rates is also expected to propel the growth of the peptic ulcer market in the future. Smoking involves inhaling and exhaling the smoke produced by burning plant-based substances such as tobacco. It is a recognized risk factor for peptic ulcer disease, as smoking damages the lining of the stomach and duodenum, reduces blood flow to the gastric tissues, and increases the production of stomach acid. These effects collectively heighten the likelihood of ulcer formation and delay healing. For instance, in November 2025, according to the Organisation for Economic Co-operation and Development, a France-based intergovernmental organization, 14.8% of individuals aged 15 years and older across OECD countries smoked daily in 2023. The highest proportions of daily smokers were observed in Türkiye, Hungary, Greece, and partner countries such as Indonesia, Bulgaria, and China, where at least one in four people smoked daily. Therefore, increasing smoking rates are driving the growth of the peptic ulcer market.

Major companies operating in the peptic ulcer market are concentrating on the development of innovative treatment approaches, such as combination therapy drug kits, to address the growing demand for effective Helicobacter pylori eradication and ulcer management. Combination therapy kits combine multiple active pharmaceutical ingredients into a single treatment regimen, enhancing patient adherence and offering a more comprehensive therapeutic approach compared to single-drug treatments. For example, in April 2023, Akums Drugs and Pharmaceuticals Ltd., an India-based manufacturer of pharmaceutical formulations and active pharmaceutical ingredients, launched Combikit, a three-drug formulation containing amoxicillin, clarithromycin, and esomeprazole. This formulation is designed to simultaneously target bacterial eradication, suppress gastric acid, and promote ulcer healing. It received approval from the Central Drugs Standard Control Organisation for the treatment of duodenal ulcers associated with Helicobacter pylori infection and for the eradication of H. pylori in patients with active or healed peptic ulcers. By integrating complementary mechanisms of action, this therapy improves treatment effectiveness, lowers ulcer recurrence rates, and enhances patient compliance, particularly in regions with a high prevalence of H. pylori infection.

Major companies operating in the peptic ulcer market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., CSL Limited, Boehringer Ingelheim International GmbH, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Zydus Lifesciences, Lupin Limited, Livzon Pharmaceutical Group Inc., Yuhan Corporation, Torrent Pharmaceuticals Ltd., Daewoong Pharmaceutical Co. Ltd., Ilyang Pharmaceutical Co, Jiangsu Carephar Pharmaceutical Co Ltd.

North America was the largest region in the peptic ulcer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptic ulcer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peptic ulcer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the peptic ulcer market by increasing costs of imported drugs, diagnostic kits, and medical devices, especially in regions like North America and Europe. These tariffs have caused temporary price increases and slowed adoption in hospital pharmacies and private clinics, while encouraging local manufacturing, supply chain diversification, and cost-optimization in pharmaceutical production.

The peptic ulcer market research report is one of a series of new reports that provides peptic ulcer market statistics, including peptic ulcer industry global market size, regional shares, competitors with a peptic ulcer market share, detailed peptic ulcer market segments, market trends and opportunities, and any further data you may need to thrive in the peptic ulcer industry. This peptic ulcer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A peptic ulcer is a lesion or open sore that develops in the lining of the stomach or the intestine, most commonly due to damage or erosion of the stomach’s protective mucosal layer or the upper portion of the small intestine known as the duodenum. Typical symptoms of peptic ulcers include upper abdominal pain or discomfort and acid reflux-related symptoms such as heartburn, which may sometimes be accompanied by nausea.

The primary disease indication types include gastritis, gastric ulcers, duodenal ulcers, and gastroesophageal reflux disease (GERD). Gastritis is defined as inflammation, irritation, or erosion of the stomach lining. Management of gastritis generally includes medications such as proton pump inhibitors along with lifestyle modifications. The drugs used in treatment include proton pump inhibitors, H2 antagonists, antibiotics, and other medications, which are distributed through channels such as hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-commerce platforms.

The peptic ulcer market consists of revenues earned by entities by providing treatment services related to peptic ulcer such as surgeries, endoscopy, blood tests, and physical exams. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptic ulcer market also includes sales of acid blockers, cytoprotective agents, bismuth subsalicylate, and mastic powder. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.